[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-001", "question": "A 68-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide presents with progressive dyspnea and fatigue. He has no chest pain or fever. His oxygen saturation is 88% on room air. CT pulmonary angiography shows no pulmonary embolism, but reveals diffuse ground-glass opacities with peripheral sparing. Bronchoalveolar lavage shows lymphocytic predominance with CD4:CD8 ratio of 0.3. Which of the following is the most appropriate next step in management?", "options": ["Discontinue enzalutamide and initiate high-dose corticosteroids", "Initiate empiric broad-spectrum antibiotics for atypical pneumonia", "Add abiraterone to his current regimen and continue enzalutamide", "Perform transbronchial biopsy to rule out lymphangitic carcinomatosis", "Start therapeutic-dose low-molecular-weight heparin for occult pulmonary embolism"], "answer": "A", "answer_index": 0, "explanation": "This presentation is classic for enzalutamide-induced interstitial pneumonitis, which typically presents with subacute dyspnea, ground-glass opacities on CT, and a lymphocytic BAL with low CD4:CD8 ratio. Immediate discontinuation of the offending agent and initiation of corticosteroids is the standard management. Antibiotics are not indicated without infectious signs, and adding abiraterone would exacerbate the drug-induced lung injury.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 68-year-old man on enzalutamide presenting with progressive dyspnea, hypoxemia (88% on room air), diffuse ground-glass opacities with peripheral sparing, and BAL showing lymphocytic predominance with CD4:CD8 ratio of 0.3. Key discriminating findings include: (1) temporal association with enzalutamide therapy, (2) CT pattern of ground-glass opacities with peripheral sparing (typical for drug-induced pneumonitis), (3) lymphocytic BAL with inverted CD4:CD8 ratio (<1.0, suggesting T-cell alveolitis), (4) exclusion of PE by CTPA, (5) absence of infectious signs (no fever). These findings strongly support drug-induced interstitial pneumonitis. Option A (discontinue enzalutamide + high-dose corticosteroids) is the established management for drug-induced pneumonitis. Option B is incorrect—no fever or infectious signs, lymphocytic pattern argues against bacterial/atypical infection. Option C would worsen drug-induced injury. Option D is unnecessary—clinical/radiologic/BAL findings are sufficient for diagnosis; biopsy reserved for diagnostic uncertainty. Option E is incorrect—PE already excluded by CTPA. The item is medically accurate, logically sound, and supports a unique best answer matching the key. Minimal fix: None needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 68-year-old man on enzalutamide presenting with progressive dyspnea, hypoxemia (88% on room air), diffuse ground-glass opacities with peripheral sparing, and BAL showing lymphocytic predominance with CD4:CD8 ratio of 0.3. Key discriminating findings include: (1) temporal association with enzalutamide therapy, (2) CT pattern of ground-glass opacities with peripheral sparing (typical for drug-induced pneumonitis), (3) lymphocytic BAL with inverted CD4:CD8 ratio (<1.0, suggesting T-cell alveolitis), (4) exclusion of PE by CTPA, (5) absence of infectious signs (no fever). These findings strongly support drug-induced interstitial pneumonitis. Option A (discontinue enzalutamide + high-dose corticosteroids) is the established management for drug-induced pneumonitis. Option B is incorrect—no fever or infectious signs, lymphocytic pattern argues against bacterial/atypical infection. Option C would worsen drug-induced injury. Option D is unnecessary—clinical/radiologic/BAL findings are sufficient for diagnosis; biopsy reserved for diagnostic uncertainty. Option E is incorrect—PE already excluded by CTPA. The item is medically accurate, logically sound, and supports a unique best answer matching the key. Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-002", "question": "A 4-month-old previously healthy infant presents with acute onset of irritability, vomiting, and lethargy. Physical examination reveals a bulging anterior fontanelle, retinal hemorrhages, and no focal neurologic deficits. Non-contrast head CT shows bilateral subdural hematomas of different ages. The infant's coagulation studies and metabolic panel are normal. Which of the following additional findings would most strongly support a diagnosis of glutaric aciduria type 1 rather than non-accidental trauma?", "options": ["Metaphyseal corner fractures on skeletal survey", "Elevated serum ammonia level", "Frontotemporal atrophy with widened Sylvian fissures on MRI", "Subarachnoid hemorrhage extending into the posterior fossa", "Elevated urine organic acids showing 3-hydroxyglutaric aciduria"], "answer": "E", "answer_index": 4, "explanation": "While glutaric aciduria type 1 can mimic non-accidental trauma with acute encephalopathy and subdural hematomas, the definitive diagnosis requires demonstration of elevated urine organic acids, specifically 3-hydroxyglutaric aciduria. Frontotemporal atrophy (option C) is a characteristic neuroimaging finding but is not diagnostic. Metaphyseal fractures strongly suggest abuse, while elevated ammonia suggests a different metabolic disorder.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a 4-month-old with subdural hematomas of different ages, retinal hemorrhages, and bulging fontanelle—classic for non-accidental trauma (NAT) but also seen in glutaric aciduria type 1 (GA-1). The question explicitly asks which finding would MOST strongly support GA-1 over NAT. Key discriminators: Option E (elevated urine 3-hydroxyglutaric acid) is the definitive biochemical diagnostic test for GA-1, making it the gold standard differentiator. Option C (frontotemporal atrophy with widened Sylvian fissures) is characteristic neuroimaging for GA-1 but not pathognomonic and can overlap with other conditions. Option A (metaphyseal fractures) strongly suggests NAT, not GA-1. Option B (elevated ammonia) suggests other metabolic disorders (urea cycle defects, organic acidemias) but is nonspecific. Option D (subarachnoid hemorrhage) doesn't discriminate between the two. The keyed answer E is uniquely diagnostic and best supported. Medical accuracy: Excellent—accurately reflects that GA-1 diagnosis requires organic acid analysis showing elevated 3-hydroxyglutaric and glutaric acids. The stem appropriately presents a diagnostic dilemma requiring biochemical confirmation. Minimal fix: None needed; item is valid and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 4-month-old with subdural hematomas of different ages, retinal hemorrhages, and bulging fontanelle—classic for non-accidental trauma (NAT) but also seen in glutaric aciduria type 1 (GA-1). The question explicitly asks which finding would MOST strongly support GA-1 over NAT. Key discriminators: Option E (elevated urine 3-hydroxyglutaric acid) is the definitive biochemical diagnostic test for GA-1, making it the gold standard differentiator. Option C (frontotemporal atrophy with widened Sylvian fissures) is characteristic neuroimaging for GA-1 but not pathognomonic and can overlap with other conditions. Option A (metaphyseal fractures) strongly suggests NAT, not GA-1. Option B (elevated ammonia) suggests other metabolic disorders (urea cycle defects, organic acidemias) but is nonspecific. Option D (subarachnoid hemorrhage) doesn't discriminate between the two. The keyed answer E is uniquely diagnostic and best supported. Medical accuracy: Excellent—accurately reflects that GA-1 diagnosis requires organic acid analysis showing elevated 3-hydroxyglutaric and glutaric acids. The stem appropriately presents a diagnostic dilemma requiring biochemical confirmation. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-003", "question": "A 55-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who failed CAR T-cell therapy 3 months ago presents with new-onset confusion and myoclonus. MRI brain shows symmetric diffusion restriction in the bilateral thalami, basal ganglia, and cerebral cortex. EEG demonstrates periodic sharp wave complexes. CSF shows 12 white cells/mm³ (90% lymphocytes), normal glucose, and elevated protein at 80 mg/dL. Which of the following is the most likely causative agent?", "options": ["Tafasitamab", "Polatuzumab vedotin", "Tisagenlecleucel", "Blinatumomab", "Brentuximab vedotin"], "answer": "C", "answer_index": 2, "explanation": "This presentation is classic for CAR T-cell therapy-related immune effector cell-associated neurotoxicity syndrome (ICANS), which can occur weeks to months after treatment. The MRI pattern of symmetric deep gray matter and cortical involvement with corresponding EEG findings is characteristic. Tisagenlecleucel is a CD19-directed CAR T-cell therapy used in DLBCL. The other agents are monoclonal antibodies or antibody-drug conjugates not typically associated with this specific delayed neurotoxicity pattern.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The stem states the patient \\\"failed CAR T-cell therapy 3 months ago,\\\" meaning CAR-T was administered in the past and is no longer the active treatment. The question asks for the \\\"most likely causative agent\\\" of current symptoms. Key discriminating findings: new-onset confusion/myoclonus, symmetric diffusion restriction in thalami/basal ganglia/cortex, periodic sharp waves on EEG, lymphocytic CSF pleocytosis. This constellation strongly suggests Creutzfeldt-Jakob disease (CJD) or a prion-like disorder, NOT delayed ICANS. ICANS typically occurs within days to weeks (rarely beyond 8 weeks) post-CAR-T, not 3 months later. The rationale conflates timing: ICANS is an acute/subacute complication during active CAR-T expansion, not a delayed phenomenon months after treatment failure. None of the listed agents (all immunotherapies for lymphoma) are causative of CJD-like presentations. Medical accuracy issue: The explanation incorrectly characterizes ICANS timing and pathophysiology. The MRI/EEG pattern described is pathognomonic for CJD, not ICANS. Minimal fix: Either (1) change stem to \\\"2 weeks after CAR-T\\\" to make ICANS plausible, or (2) add \\\"JC virus\\\" as an option for PML, or (3) acknowledge this is a CJD mimic and provide appropriate differential options.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The stem states the patient \"failed CAR T-cell therapy 3 months ago,\" meaning CAR-T was administered in the past and is no longer the active treatment. The question asks for the \"most likely causative agent\" of current symptoms. Key discriminating findings: new-onset confusion/myoclonus, symmetric diffusion restriction in thalami/basal ganglia/cortex, periodic sharp waves on EEG, lymphocytic CSF pleocytosis. This constellation strongly suggests Creutzfeldt-Jakob disease (CJD) or a prion-like disorder, NOT delayed ICANS. ICANS typically occurs within days to weeks (rarely beyond 8 weeks) post-CAR-T, not 3 months later. The rationale conflates timing: ICANS is an acute/subacute complication during active CAR-T expansion, not a delayed phenomenon months after treatment failure. None of the listed agents (all immunotherapies for lymphoma) are causative of CJD-like presentations. Medical accuracy issue: The explanation incorrectly characterizes ICANS timing and pathophysiology. The MRI/EEG pattern described is pathognomonic for CJD, not ICANS. Minimal fix: Either (1) change stem to \"2 weeks after CAR-T\" to make ICANS plausible, or (2) add \"JC virus\" as an option for PML, or (3) acknowledge this is a CJD mimic and provide appropriate differential options.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-004", "question": "A critically ill patient with septic shock on norepinephrine (0.3 mcg/kg/min) and vasopressin (0.03 units/min) develops refractory hypotension. Transthoracic echocardiogram shows a hyperdynamic left ventricle with collapsing mitral inflow pattern. Which of the following interventions is most likely to improve hemodynamics without increasing myocardial oxygen demand?", "options": ["Initiate dobutamine infusion at 5 mcg/kg/min", "Add phenylephrine infusion to target MAP >65 mmHg", "Administer 500 mL 5% albumin bolus", "Start angiotensin II infusion at 20 ng/kg/min", "Increase norepinephrine to 0.5 mcg/kg/min"], "answer": "D", "answer_index": 3, "explanation": "The echocardiographic findings suggest distributive shock with relative hypovolemia. Angiotensin II acts via AT1 receptors to cause vasoconstriction without significant inotropic effects, making it ideal for this scenario without increasing myocardial oxygen demand. Dobutamine increases myocardial demand, phenylephrine causes pure alpha-agonism with potential reflex bradycardia, fluid bolus may be insufficient in vasoplegic shock, and increasing norepinephrine adds beta-1 effects that increase oxygen consumption.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes septic shock with refractory hypotension on dual vasopressors, with echo showing hyperdynamic LV and collapsing mitral inflow (suggesting distributive shock with relative hypovolemia). The question asks for intervention improving hemodynamics without increasing myocardial oxygen demand. Key stem clues: hyperdynamic LV, collapsing inflow pattern, already on norepinephrine 0.3 mcg/kg/min and vasopressin 0.03 units/min. Main logical issue: Both angiotensin II (D) and phenylephrine (B) are pure vasoconstrictors without direct inotropic effects, making them equally defensible. The rationale dismisses phenylephrine citing 'potential reflex bradycardia,' but this is not a contraindication and doesn't increase myocardial oxygen demand—it may actually reduce it. The collapsing mitral inflow suggests need for preload optimization, making albumin (C) also defensible despite vasoplegic state. Medical accuracy issue: The claim that phenylephrine increases oxygen consumption via reflex bradycardia is incorrect; reflex bradycardia typically reduces myocardial demand. Norepinephrine at 0.3 mcg/kg/min has predominantly alpha effects at this dose, making the distinction from phenylephrine less clear. Minimal fix: Add specific contraindication to phenylephrine (e.g., severe bradycardia) or specify angiotensin II as preferred in catecholamine-resistant shock per guidelines.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes septic shock with refractory hypotension on dual vasopressors, with echo showing hyperdynamic LV and collapsing mitral inflow (suggesting distributive shock with relative hypovolemia). The question asks for intervention improving hemodynamics without increasing myocardial oxygen demand. Key stem clues: hyperdynamic LV, collapsing inflow pattern, already on norepinephrine 0.3 mcg/kg/min and vasopressin 0.03 units/min. Main logical issue: Both angiotensin II (D) and phenylephrine (B) are pure vasoconstrictors without direct inotropic effects, making them equally defensible. The rationale dismisses phenylephrine citing 'potential reflex bradycardia,' but this is not a contraindication and doesn't increase myocardial oxygen demand—it may actually reduce it. The collapsing mitral inflow suggests need for preload optimization, making albumin (C) also defensible despite vasoplegic state. Medical accuracy issue: The claim that phenylephrine increases oxygen consumption via reflex bradycardia is incorrect; reflex bradycardia typically reduces myocardial demand. Norepinephrine at 0.3 mcg/kg/min has predominantly alpha effects at this dose, making the distinction from phenylephrine less clear. Minimal fix: Add specific contraindication to phenylephrine (e.g., severe bradycardia) or specify angiotensin II as preferred in catecholamine-resistant shock per guidelines.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-005", "question": "A 7-year-old boy presents with acute cerebellar ataxia following varicella infection 2 weeks prior. MRI shows T2 hyperintensity restricted to the cerebellar hemispheres. CSF demonstrates 15 lymphocytes/mm³, normal glucose, and elevated IgG index. Which of the following autoantibodies is most specific for this condition?", "options": ["Anti-GAD65", "Anti-Hu", "Anti-Yo", "Anti-Tr/DNER", "Anti-mGluR1"], "answer": "D", "answer_index": 3, "explanation": "Post-varicella acute cerebellar ataxia is associated with anti-Tr/DNER (delta/notch-like epidermal growth factor-related receptor) antibodies in a significant proportion of cases. This antibody is highly specific for paraneoplastic cerebellar degeneration in Hodgkin lymphoma but also occurs in post-infectious contexts. Anti-Yo and anti-Hu are associated with gynecological/breast cancers and small cell lung cancer respectively. Anti-mGluR1 is seen in Hodgkin-related ataxia, while anti-GAD65 is associated with stiff-person syndrome.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key is not the best answer. The stem describes post-varicella acute cerebellar ataxia in a 7-year-old child, a classic post-infectious immune-mediated syndrome. Key discriminating findings: pediatric age, temporal relationship to varicella (2 weeks prior), acute cerebellar ataxia, MRI showing cerebellar-restricted T2 hyperintensity, and CSF with mild lymphocytosis and elevated IgG index. This clinical picture is pathognomonic for post-infectious acute cerebellar ataxia (ACA), which is typically NOT associated with specific autoantibodies. Anti-Tr/DNER (option D, the keyed answer) is indeed associated with paraneoplastic cerebellar degeneration, primarily in Hodgkin lymphoma patients - not post-infectious pediatric ACA. The rationale incorrectly claims anti-Tr/DNER occurs in post-infectious contexts without evidence support. Post-varicella ACA is generally seronegative or may show non-specific antibodies. None of the listed antibodies (all paraneoplastic) are characteristic of post-infectious ACA. The item appears to conflate paraneoplastic and post-infectious cerebellar syndromes. Medical accuracy issue: fundamental misattribution of antibody associations. Minimal fix: Either change the clinical scenario to Hodgkin lymphoma with cerebellar degeneration (supporting option D) or add 'None of the above' as the correct answer for this post-infectious presentation.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key is not the best answer. The stem describes post-varicella acute cerebellar ataxia in a 7-year-old child, a classic post-infectious immune-mediated syndrome. Key discriminating findings: pediatric age, temporal relationship to varicella (2 weeks prior), acute cerebellar ataxia, MRI showing cerebellar-restricted T2 hyperintensity, and CSF with mild lymphocytosis and elevated IgG index. This clinical picture is pathognomonic for post-infectious acute cerebellar ataxia (ACA), which is typically NOT associated with specific autoantibodies. Anti-Tr/DNER (option D, the keyed answer) is indeed associated with paraneoplastic cerebellar degeneration, primarily in Hodgkin lymphoma patients - not post-infectious pediatric ACA. The rationale incorrectly claims anti-Tr/DNER occurs in post-infectious contexts without evidence support. Post-varicella ACA is generally seronegative or may show non-specific antibodies. None of the listed antibodies (all paraneoplastic) are characteristic of post-infectious ACA. The item appears to conflate paraneoplastic and post-infectious cerebellar syndromes. Medical accuracy issue: fundamental misattribution of antibody associations. Minimal fix: Either change the clinical scenario to Hodgkin lymphoma with cerebellar degeneration (supporting option D) or add 'None of the above' as the correct answer for this post-infectious presentation.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-006", "question": "A 42-year-old woman with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) achieves complete morphological remission after induction chemotherapy. Minimal residual disease (MRD) testing by flow cytometry shows 0.01% blasts. Which of the following factors would most strongly indicate proceeding to allogeneic hematopoietic stem cell transplantation in first complete remission rather than continuing with chemotherapy plus a tyrosine kinase inhibitor?", "options": ["Presence of IKZF1 deletion", "Age >40 years", "MRD positivity after consolidation therapy", "White blood cell count >30,000/μL at diagnosis", "Presence of additional cytogenetic abnormalities besides t(9;22)"], "answer": "C", "answer_index": 2, "explanation": "In Ph+ ALL, MRD positivity after consolidation therapy is the strongest predictor of poor outcome with chemotherapy/TKI alone and is a clear indication for allogeneic transplantation in first remission. While age >40, high WBC, IKZF1 deletion, and additional abnormalities are adverse prognostic factors, contemporary TKI-based regimens can overcome many of these. Persistent MRD after intensive therapy indicates resistant disease requiring transplant for cure.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question asks which factor most strongly indicates proceeding to allogeneic HSCT in first complete remission for Ph+ ALL. Key stem clues: patient achieved complete morphological remission with MRD 0.01% after induction. The question focuses on factors that would drive transplant decision. Choice C (MRD positivity after consolidation) is the strongest indicator because persistent MRD after intensive consolidation therapy demonstrates treatment-resistant disease and is the most robust predictor of relapse, making transplant necessary. This aligns with current guidelines emphasizing MRD as the primary driver of transplant decisions in Ph+ ALL. Choices A, B, D, and E represent baseline adverse prognostic factors that modern TKI-based regimens (imatinib, dasatinib, ponatinib) can often overcome, making them less decisive for transplant indication compared to post-treatment MRD status. The item is medically accurate and logically sound. The stem provides sufficient context (newly diagnosed Ph+ ALL, post-induction remission with low MRD) to discriminate among options. No contradictions or underspecification present. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question asks which factor most strongly indicates proceeding to allogeneic HSCT in first complete remission for Ph+ ALL. Key stem clues: patient achieved complete morphological remission with MRD 0.01% after induction. The question focuses on factors that would drive transplant decision. Choice C (MRD positivity after consolidation) is the strongest indicator because persistent MRD after intensive consolidation therapy demonstrates treatment-resistant disease and is the most robust predictor of relapse, making transplant necessary. This aligns with current guidelines emphasizing MRD as the primary driver of transplant decisions in Ph+ ALL. Choices A, B, D, and E represent baseline adverse prognostic factors that modern TKI-based regimens (imatinib, dasatinib, ponatinib) can often overcome, making them less decisive for transplant indication compared to post-treatment MRD status. The item is medically accurate and logically sound. The stem provides sufficient context (newly diagnosed Ph+ ALL, post-induction remission with low MRD) to discriminate among options. No contradictions or underspecification present. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-007", "question": "A 65-year-old man with atrial fibrillation on apixaban presents with acute onset of aphasia and right hemiparesis. CT head shows a 3 cm left MCA territory infarct with no hemorrhage. Last apixaban dose was 4 hours ago. NIH Stroke Scale is 18. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator immediately", "Give 4-factor prothrombin complex concentrate followed by tPA", "Perform emergent mechanical thrombectomy without thrombolysis", "Administer andexanet alfa followed by mechanical thrombectomy", "Give idarucizumab empirically followed by mechanical thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "For large vessel occlusion strokes in patients on direct oral anticoagulants (DOACs) with recent dosing, mechanical thrombectomy without thrombolysis is recommended due to the increased risk of hemorrhagic transformation with tPA. Andexanet alfa is a reversal agent for factor Xa inhibitors but is not routinely recommended prior to thrombectomy unless there is life-threatening bleeding. Idarucizumab is for dabigatran reversal. PCC before tPA still carries bleeding risk and delays intervention.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 65-year-old on apixaban (last dose 4 hours ago) with acute large vessel occlusion stroke (NIHSS 18, 3cm left MCA infarct). Key discriminating findings: recent DOAC use, large vessel occlusion, no hemorrhage on CT, within potential intervention window. The question asks for \\\"most appropriate acute intervention.\\\" Option C (mechanical thrombectomy alone) is keyed as correct, citing bleeding risk with tPA in recent DOAC patients. However, Option D (andexanet alfa + thrombectomy) is equally defensible. Current guidelines (AHA/ASA 2019) suggest considering reversal agents for patients on DOACs within therapeutic window, particularly with recent dosing (<4-6 hours). While andexanet alfa isn't mandatory, it's not contraindicated and may reduce hemorrhagic risk. The rationale dismisses Option D as \\\"not routinely recommended\\\" but doesn't establish C as uniquely superior—both are reasonable approaches depending on institutional protocols. The item is underspecified regarding time from symptom onset (critical for tPA eligibility) and doesn't provide sufficient evidence to exclude reversal agent use. Medical accuracy is good (score 4) but the logical validity fails due to two defensible options. Minimal fix: Specify symptom onset time and clarify institutional protocol regarding reversal agents, or add contraindication to andexanet alfa.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 65-year-old on apixaban (last dose 4 hours ago) with acute large vessel occlusion stroke (NIHSS 18, 3cm left MCA infarct). Key discriminating findings: recent DOAC use, large vessel occlusion, no hemorrhage on CT, within potential intervention window. The question asks for \"most appropriate acute intervention.\" Option C (mechanical thrombectomy alone) is keyed as correct, citing bleeding risk with tPA in recent DOAC patients. However, Option D (andexanet alfa + thrombectomy) is equally defensible. Current guidelines (AHA/ASA 2019) suggest considering reversal agents for patients on DOACs within therapeutic window, particularly with recent dosing (<4-6 hours). While andexanet alfa isn't mandatory, it's not contraindicated and may reduce hemorrhagic risk. The rationale dismisses Option D as \"not routinely recommended\" but doesn't establish C as uniquely superior—both are reasonable approaches depending on institutional protocols. The item is underspecified regarding time from symptom onset (critical for tPA eligibility) and doesn't provide sufficient evidence to exclude reversal agent use. Medical accuracy is good (score 4) but the logical validity fails due to two defensible options. Minimal fix: Specify symptom onset time and clarify institutional protocol regarding reversal agents, or add contraindication to andexanet alfa.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-008", "question": "A 3-year-old child with DiGeorge syndrome (22q11.2 deletion) presents with hypocalcemic seizures. Correction of calcium with intravenous calcium gluconate and calcitriol is initiated. Which of the following immunologic parameters, if present, would be an absolute contraindication to live viral vaccination?", "options": ["CD4+ T cell count <500 cells/μL", "Absent thymic shadow on chest radiograph", "Low but detectable T cell receptor excision circles (TRECs)", "Severely reduced proliferative response to phytohemagglutinin", "Complete absence of CD3+ T cells by flow cytometry"], "answer": "E", "answer_index": 4, "explanation": "Complete absence of CD3+ T cells indicates severe combined immunodeficiency (SCID) phenotype within DiGeorge spectrum, which is an absolute contraindication to live vaccines due to risk of disseminated infection. Reduced proliferative responses (option D) indicate functional impairment but not complete absence. Low TRECs suggest poor thymic output but not necessarily SCID. CD4 count and thymic shadow are not definitive contraindications alone.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question asks for an absolute contraindication to live viral vaccination in DiGeorge syndrome. Key stem clues: 3-year-old with 22q11.2 deletion presenting with hypocalcemic seizures (classic DiGeorge). The critical discriminator is identifying which parameter represents complete immunodeficiency. Option E (complete absence of CD3+ T cells) correctly identifies SCID phenotype, an absolute contraindication to live vaccines per CDC/ACIP guidelines. Option D (severely reduced proliferative response) indicates severe dysfunction but not complete absence—this represents partial DiGeorge, where live vaccines may still be contraindicated but the question asks for absolute contraindication tied to a specific parameter. Option B (absent thymic shadow) is common in DiGeorge but doesn't definitively indicate SCID. Option C (low TRECs) suggests poor thymic output but some T cell presence. Option A (CD4<500) is insufficient alone. The keyed answer is medically accurate: complete absence of CD3+ cells defines SCID, where live vaccines cause disseminated infection (documented with BCG, VZV, rotavirus). No other option represents as absolute a contraindication. Minimal fix: None needed; item is logically valid and medically sound.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question asks for an absolute contraindication to live viral vaccination in DiGeorge syndrome. Key stem clues: 3-year-old with 22q11.2 deletion presenting with hypocalcemic seizures (classic DiGeorge). The critical discriminator is identifying which parameter represents complete immunodeficiency. Option E (complete absence of CD3+ T cells) correctly identifies SCID phenotype, an absolute contraindication to live vaccines per CDC/ACIP guidelines. Option D (severely reduced proliferative response) indicates severe dysfunction but not complete absence—this represents partial DiGeorge, where live vaccines may still be contraindicated but the question asks for absolute contraindication tied to a specific parameter. Option B (absent thymic shadow) is common in DiGeorge but doesn't definitively indicate SCID. Option C (low TRECs) suggests poor thymic output but some T cell presence. Option A (CD4<500) is insufficient alone. The keyed answer is medically accurate: complete absence of CD3+ cells defines SCID, where live vaccines cause disseminated infection (documented with BCG, VZV, rotavirus). No other option represents as absolute a contraindication. Minimal fix: None needed; item is logically valid and medically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-009", "question": "A patient with glioblastoma on temozolomide and dexamethasone develops progressive headache, visual changes, and diabetes insipidus. MRI shows thickening and enhancement of the pituitary stalk with loss of the posterior pituitary bright spot. CSF cytology is negative. Which of the following findings would most strongly support a diagnosis of lymphocytic hypophysitis over pituitary metastasis?", "options": ["Presence of anti-pituitary antibodies", "Elevated CSF beta-2 transferrin", "Simultaneous involvement of the pineal gland", "Rapid improvement with high-dose corticosteroids", "Association with other autoimmune endocrine deficiencies"], "answer": "E", "answer_index": 4, "explanation": "Lymphocytic hypophysitis frequently presents with other autoimmune endocrine deficiencies (thyroiditis, adrenalitis, diabetes mellitus type 1), while pituitary metastases typically occur in isolation. Anti-pituitary antibodies have poor sensitivity/specificity. CSF beta-2 transferrin indicates CSF leak. Pineal involvement suggests germinoma. Steroid responsiveness occurs in both conditions but is more dramatic in hypophysitis; however, association with other autoimmune conditions is more specific.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient on dexamethasone (immunosuppressive) with pituitary stalk thickening and diabetes insipidus. The question asks which finding most strongly supports lymphocytic hypophysitis over metastasis. Option E (autoimmune endocrine deficiencies) is keyed as correct, citing association with autoimmune conditions. However, Option D (rapid improvement with high-dose corticosteroids) is equally or more defensible: lymphocytic hypophysitis characteristically responds dramatically to steroids, while metastases typically do not respond or respond minimally. The rationale acknowledges steroid responsiveness occurs in both but is \\\"more dramatic in hypophysitis\\\"—this dramatic response is clinically the hallmark distinguishing feature. The patient is already on dexamethasone, making the clinical context of steroid response highly relevant. Option E's association with other autoimmune conditions is supportive but less specific in acute differentiation, as isolated hypophysitis occurs commonly. Medical accuracy issue: The item conflates chronic association patterns with acute diagnostic discriminators. Both D and E have merit, creating a near-tie. Minimal fix: Reframe to ask for \\\"chronic pattern\\\" rather than \\\"most strongly support\\\" to favor E, or specify \\\"in a steroid-naive patient\\\" to favor D uniquely.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient on dexamethasone (immunosuppressive) with pituitary stalk thickening and diabetes insipidus. The question asks which finding most strongly supports lymphocytic hypophysitis over metastasis. Option E (autoimmune endocrine deficiencies) is keyed as correct, citing association with autoimmune conditions. However, Option D (rapid improvement with high-dose corticosteroids) is equally or more defensible: lymphocytic hypophysitis characteristically responds dramatically to steroids, while metastases typically do not respond or respond minimally. The rationale acknowledges steroid responsiveness occurs in both but is \"more dramatic in hypophysitis\"—this dramatic response is clinically the hallmark distinguishing feature. The patient is already on dexamethasone, making the clinical context of steroid response highly relevant. Option E's association with other autoimmune conditions is supportive but less specific in acute differentiation, as isolated hypophysitis occurs commonly. Medical accuracy issue: The item conflates chronic association patterns with acute diagnostic discriminators. Both D and E have merit, creating a near-tie. Minimal fix: Reframe to ask for \"chronic pattern\" rather than \"most strongly support\" to favor E, or specify \"in a steroid-naive patient\" to favor D uniquely.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-010", "question": "A neonate born at 32 weeks gestation develops necrotizing enterocolitis (NEC) on day 10 of life. During laparotomy, approximately 40% of the small bowel appears necrotic. Which of the following intraoperative findings would mandate creation of a high jejunostomy rather than primary anastomosis?", "options": ["Involvement of the ileocecal valve", "Necrosis extending to within 5 cm of the ligament of Treitz", "Presence of pneumatosis intestinalis in the remaining bowel", "Concurrent isolated perforation of the gastric fundus", "Development of abdominal compartment syndrome during surgery"], "answer": "B", "answer_index": 1, "explanation": "Necrosis extending to within 5 cm of the ligament of Treitz indicates near-total small bowel loss, requiring high jejunostomy to preserve the maximal possible length of viable bowel for future adaptation and prevent anastomotic leakage in compromised tissue. Ileocecal valve involvement is important for absorption but doesn't dictate anastomosis vs ostomy. Pneumatosis may be present in non-necrotic bowel. Gastric perforation is managed separately. Abdominal compartment syndrome may require temporary closure but not necessarily jejunostomy.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem asks what finding would \\\"mandate\\\" high jejunostomy rather than primary anastomosis in NEC with 40% small bowel necrosis. Key stem clues: 32-week neonate, day 10 NEC, 40% small bowel necrotic at laparotomy. The keyed answer (B) assumes necrosis within 5 cm of ligament of Treitz leaves insufficient proximal bowel for safe anastomosis. However, the stem never specifies WHERE the initial 40% necrosis is located—it could be distal ileum, mid-jejunum, or scattered. Without knowing the baseline distribution, we cannot determine if option B represents \\\"additional\\\" proximal extension or is already included in the 40%. Option E (abdominal compartment syndrome) is also defensible: ACS during surgery often mandates damage-control approach with ostomy and temporary abdominal closure rather than primary anastomosis, which risks anastomotic failure under elevated intra-abdominal pressure. The item conflates anatomic considerations (bowel length preservation) with physiologic contraindications to anastomosis (hemodynamic instability, ACS). Main medical issue: the rationale for B is reasonable but not absolute; surgeons may still attempt anastomosis with short bowel if tissue viable. Minimal fix: specify baseline necrosis location (e.g., \\\"distal 40% of small bowel\\\") and clarify that option B represents NEW proximal extension discovered intraoperatively, making it the unique contraindication to anastomosis.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem asks what finding would \"mandate\" high jejunostomy rather than primary anastomosis in NEC with 40% small bowel necrosis. Key stem clues: 32-week neonate, day 10 NEC, 40% small bowel necrotic at laparotomy. The keyed answer (B) assumes necrosis within 5 cm of ligament of Treitz leaves insufficient proximal bowel for safe anastomosis. However, the stem never specifies WHERE the initial 40% necrosis is located—it could be distal ileum, mid-jejunum, or scattered. Without knowing the baseline distribution, we cannot determine if option B represents \"additional\" proximal extension or is already included in the 40%. Option E (abdominal compartment syndrome) is also defensible: ACS during surgery often mandates damage-control approach with ostomy and temporary abdominal closure rather than primary anastomosis, which risks anastomotic failure under elevated intra-abdominal pressure. The item conflates anatomic considerations (bowel length preservation) with physiologic contraindications to anastomosis (hemodynamic instability, ACS). Main medical issue: the rationale for B is reasonable but not absolute; surgeons may still attempt anastomosis with short bowel if tissue viable. Minimal fix: specify baseline necrosis location (e.g., \"distal 40% of small bowel\") and clarify that option B represents NEW proximal extension discovered intraoperatively, making it the unique contraindication to anastomosis.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}]